A randomised phase II trial of temozolomide with or without cannabinoids in patients with recurrent glioblastoma (ARISTOCRAT): protocol for a multi-centre, double-blind, placebo-controlled trial

A randomised phase II trial of temozolomide with or without cannabinoids in patients with recurrent glioblastoma (ARISTOCRAT): protocol for a multi-centre, double-blind, placebo-controlled trial

Abstract Background Glioblastoma (GBM) is the most common adult malignant brain tumour, with an incidence of 5 per 100,000 per year in England. Patients with tumours showing O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation represent around 40% of newly diagnosed GBM. Relapse/tumour...

Full description

Bibliographic Details
Main Authors: Divyalakshmi Bhaskaran, Joshua Savage, Amit Patel, Fiona Collinson, Rhys Mant, Florien Boele, Lucy Brazil, Sara Meade, Peter Buckle, Siân Lax, Lucinda Billingham, Susan C. Short
Format: Article
Language:English
Published: BMC 2024-01-01
Series:BMC Cancer
Subjects:
Randomised phase II trial
Glioblastoma
Cannabinoids
Sativex
Nabiximols
Brain cancer
Online Access:https://doi.org/10.1186/s12885-023-11792-4

Internet

https://doi.org/10.1186/s12885-023-11792-4

Similar Items